Publication: Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand
7
Issued Date
2016-07-03
Resource Type
ISSN
17448379
14737167
14737167
Other identifier(s)
2-s2.0-84950153314
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Pharmacoeconomics and Outcomes Research. Vol.16, No.4 (2016), 525-536
Suggested Citation
Watsamon Thongsri, Thanaporn Bussabawalai, Pattara Leelahavarong, Suthep Wanitkun, Kritvikrom Durongpisitkul, Usa Chaikledkaew, Yot Teerawattananon Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand. Expert Review of Pharmacoeconomics and Outcomes Research. Vol.16, No.4 (2016), 525-536. doi:10.1586/14737167.2016.1120672 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/41297
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand
Abstract
© 2015 Informa UK Limited, trading as Taylor & Francis Group. Objective: This study aims to compare the lifetime costs and health outcomes of both first-line and sequential combination treatments with standard treatment for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) (PAH-CHD) patients. Methods: A cost-utility analysis was performed using a Markov model based on a societal perspective. One-way and probabilistic sensitivity analyses were performed to investigate the effect of parameter uncertainty. Results: As first-line treatments, both beraprost (incremental cost-effectiveness ratio (ICER) = 192,752 and 201,308 Thai baht (THB) per quality-adjusted life year (QALY) gained) and sildenafil (ICER = 249,770 and 226,802 THB per QALY gained) seemed cost-effective for PAH-CHD patients aged ≤30 years in functional classes II and III, respectively, while no treatment was cost-effective for the sequential combination therapy. Conclusions: Sildenafil should be included in the National Drug List of Essential Medicines as the first-line treatment for PAH-CHD, and its price per dose should be negotiated to be reduced by 43–57%.